What Is CJC-1295?

CJC-1295 is a synthetic peptide built around growth-hormone-releasing hormone, the signal that prompts the pituitary to release growth hormone. The form in the catalogue is the no-DAC version, a stabilised analogue of the GHRH(1-29) fragment. This profile covers what the molecule is, how it relates to natural GHRH, and the research areas it appears in. It concerns the compound and its study, and says nothing about use.

The natural starting point is GHRH(1-29), the active fragment of growth-hormone-releasing hormone, which on its own is cleared quickly. CJC-1295 carries a small set of amino-acid substitutions chosen to slow that breakdown and give a more stable research peptide, sometimes labelled modified GRF (1-29). A separate variant adds a Drug Affinity Complex group for a longer profile; the material here is the no-DAC form. Background on assembling analogues of this kind is in how peptides are manufactured.

As a roughly thirty-residue peptide based on GHRH(1-29), CJC-1295 keeps the part of the sequence that meets the GHRH receptor while differing at a few positions to resist the enzymes that would otherwise shorten its life. The material is handled as a lyophilised powder, as listed on the CJC-1295 product page; for reading the substitutions in a specification, our note on peptide sequence notation is a useful reference.

CJC-1295 draws interest as a GHRH-receptor agonist, which makes it a tool for studying the secretagogue pathway: the chain of signalling that governs growth-hormone release at the pituitary. It is frequently discussed alongside a different class of secretagogue, the growth-hormone-releasing peptides such as ipamorelin, because the two classes act through separate receptors and are often examined together in receptor pharmacology.

The growth-hormone secretagogue pathway runs through the somatotroph cells of the anterior pituitary, where the GHRH receptor sits, and CJC-1295 is studied as a defined way to engage that receptor. Natural GHRH is released in pulses and cleared quickly, so a stabilised analogue gives researchers a longer-lived, more controlled stimulus for characterising the receptor and the signalling that follows. Because the no-DAC form lacks the albumin-binding group of the DAC variant, it is comparatively shorter-acting, which suits a study that wants a brief, well-bounded interaction. This describes the receptor biology and why the analogue is of laboratory interest, not any property of the material in use.

Published work involving CJC-1295 sits within growth-hormone secretagogue research: characterising how the analogue engages the GHRH receptor, how the stabilising substitutions change its persistence in model systems, and how it behaves next to related compounds. These describe the molecule in research settings, with no implication about use. Other secretagogue-related materials appear in the research catalogue.

CJC-1295 is best understood as one analogue within a well-studied signalling system rather than an isolated molecule, and the no-DAC and DAC forms are distinct enough that the literature keeps them separate. The CJC-1295 research overview looks at the investigated mechanisms and the limits of the evidence.

All products are supplied strictly for laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or food. Not for diagnostic or therapeutic use. The material on this page is educational and factual: it summarises areas of published scientific investigation and general laboratory practice. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance, or outcomes. Where a specific product specification or safety data sheet is provided with a material, that document is the definitive reference and takes precedence over any general information given here.